Although those compounds are predominantly used in the treatment of male erectile dysfunction and pulmonary hypertension, it was shown (Shirvaliloo, 2021) that in the presence of SARS-CoV-2 infection, PDE5 inhibitors prevent thromboembolism caused by inflammatory processes in COVID-19 patients via NO/cGMP pathway and are potent inhibitors of 3CLpro (Jin et al., 2020). This evidence concerns the gene PDE5A and pulmonary arterial hypertension.